QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease

This randomized, double-blind, crossover study compared the efficacy and safety of once-daily QVA149 300/50 mg, indacaterol 300 mg, indacaterol 600 mg, or placebo in 154 patients with moderate-to-severe COPD. The primary endpoint was trough FEV1 on Day 7; secondary endpoints included trough FEV1 on Day 1, trough FVC on Days 1 and 7, and individual time point FEV1 and FVC on Days 1 and 7. All patients underwent lung function testing at a central laboratory using the Vitalograph Pneumotrac spirometer.